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192Vascular remodeling and intimal hyperplasia in
a novel murine model of arteriovenous ﬁstula failure
Chun-Yu Wong, MD,a,b Margreet R. de Vries, BSc,b,c Yang Wang, MD,d Joost R. van der Vorst, MD,c
Alexander L. Vahrmeijer, MD, PhD,c Anton Jan van Zonneveld, PhD,a,b Prabir Roy-Chaudhury, MD, PhD,d
Ton J. Rabelink, MD, PhD,a,b Paul H. A. Quax, PhD,b,c and Joris I. Rotmans, MD, PhD,a,b Leiden,
The Netherlands; and Cincinnati, Ohio
Objective: The arteriovenous ﬁstula (AVF) still suffers from a high number of failures caused by insufﬁcient outward
remodeling and intimal hyperplasia (IH) formation from which the exact mechanism is largely unknown. A suitable
animal model is of vital importance in the unraveling of the underlying pathophysiology. However, current murine
models of AVF failure do not incorporate the surgical conﬁguration that is commonly used in humans. Because the
hemodynamic proﬁle is one of the key determinants that play a role in vascular remodeling in the AVF, it is preferable to
use this same conﬁguration in an animal model. Here we describe a novel murine model of AVF failure in which the
conﬁguration (end-to-side) is similar to what is most frequently performed in humans.
Methods: An AVF was created in 45 C57BL/6 mice by anastomosing the end of a branch of the external jugular vein to the
side of the common carotid artery with interrupted sutures. The AVFs were harvested and analyzed histologically at days
7, 14, and 28. Identical veins of unoperated-on mice served as controls. Intravenous near-infrared ﬂuorescent ﬂuo-
rophores were used to assess the patency of the ﬁstula.
Results: The patency rates at days 7, 14, and 28 days were 88%, 90%, and 50%, respectively. The mean circumference
increased up to day 14, with a maximum 1.4-fold increase at day 7 compared with the control group (1.82 6 0.7 vs
1.336 0.3 mm; P[ .443). Between days 14 and 28, the circumference remained constant (2.366 0.2 vs 2.456 0.2 mm;
P[ .996). At 7 days after surgery, the intimal area consisted mainly of an acellular layer that was structurally analogous
to a focal adherent thrombus. Starting at 14 days after surgery, venous IH increased signiﬁcantly compared with the
unoperated-on group (14 days: 115,090 6 22,594 mm2, 28 days: 234,619 6 47,828 mm2, unoperated group: 2368 6
1056 mm2; P[ .001 and P < .001, respectively) and was mainly composed of cells positive for a-smooth muscle actin. We
observed leukocytes in the adventitial side of the vein at all time points.
Conclusions: Our novel murine AVF model, which incorporates a clinically relevant conﬁguration of the anastomosis,
displays similar features that are characteristic of failing human AVFs. Moreover, our ﬁndings suggest that coagulation
and inﬂammation could both potentially play an important role in the formation of IH and subsequent AVF failure.
Near-infrared ﬂuoroscopy was a suitable alternative for conventional imaging techniques. This murine AVF-model is
a valuable addition to the AVF animal model arsenal. (J Vasc Surg 2014;59:192-201.)
Clinical Relevance: The autologous arteriovenous ﬁstula is considered the preferred choice for vascular access in hemo-
dialysis. However, this type of vascular access suffers from a high failure rate, of which the exact pathophysiology is poorly
understood. The use of a clinically relevant murine model provides us with a tool to unravel the pathophysiology and also
to develop new therapeutic strategies that can improve the patency of the arteriovenous ﬁstula in hemodialysis patients.the Department of Nephrology,a Einthoven Laboratory for Experi-
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://dx.doi.org/10.1016/j.jvs.2013.02.242A durable vascular access is vitally important for patients
who require chronic hemodialysis. In view of their superior
patency rates, the construction of native arteriovenous
ﬁstulas (AVFs) is currently the preferred choice for vascular
access. However, the utility of AVFs is hampered by two
distinct causes of failure: (1) an initial failure to mature and
(2) the later development of stenotic lesions in the venous
outﬂow tract. The exact pathophysiology that results in
maturation failure is unclear, although intimal hyperplasia
(IH) and impaired outward remodeling (OR) both seem
to contribute.1 Various studies report poor 1-year primary
patency rates of AVFs not exceeding 60% to 65%.2-4
To date, numerous animal models5-17 have been
designed to study AVF failure. Large animals, such as
pigs, are more suitable for intervention studies, but murine
Fig 1. Surgical procedure. A, Dissection of the carotid artery (a) and external jugular vein (v). B, After placement of
vascular clamps and ligation of the vein, an incision was made in the artery, followed by the transection of the vein. C,
After the front side of the anastomosis is completed with interrupted sutures, the backside is exposed using a suture wire
and by simultaneously twisting the vascular clamps 180. D, Blood ﬂow direction (arrows) in the arteriovenous ﬁstula
(AVF). E, Photograph of completed AVF. The white arrow depicts blood ﬂow in the artery, and the asterisk (*)
designates the venous outﬂow tract.
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in the molecular mechanisms underlying this pathologic
process due to the availability of transgenic mice.
In previous studies, two groups have described
a murine AVF model in which the ﬁstula was constructed
in an end-to-end manner.7,17 In 2006, an improved model
was introduced by Castier et al5,18 where the end of the
common carotid artery is connected to the side of the
external jugular vein. However, AVFs in hemodialysis
patients are usually constructed by anastomosing the end
of a vein to the side of an artery. The exact conﬁguration
of the AVF is crucial because it determines the hemody-
namic proﬁle,19 an important contributor to endothelial
dysfunction and subsequent development of IH.20-22
Therefore, incorporating an AVF conﬁguration resembling
the human AVF is preferable. In the present study,
we developed a novel murine model with an identical
anatomic conﬁguration as that used in humans. In our
analysis, we focused on OR as well as the formation of
IH in the venous outﬂow tract.
METHODS
The Leiden University Medical Center Institutional
Committee for Animal Welfare approved all experiments.
Animals and study design. The study used 45 male
C57bl6 mice (Charles River, Wilmington, Mass) aged 8
to 13 weeks. Unilateral AVFs were created in an end-to-
side manner between the dorsomedial branch of the
external jugular vein and the common carotid artery. Theanimals were euthanized at days 7, 14, and 28 after the
surgical procedure. Identical veins of unoperated-on mice
served as controls.
Anesthesia, analgesia, and anticoagulant therapy.
At the start of the procedure, animals were injected sub-
cutaneously with buprenorphine (0.1mg/kg;MSD,White-
house Station, NJ) and 0.5 mL saline. Isoﬂurane inhalation
anesthesia with oxygen-enriched (40%) air was used, with
isoﬂurane concentrations of 4% for induction and 1.5%
for maintenance. To prevent acute AVF thrombosis, ace-
tylsalicylic acid (Sigma-Aldrich, St. Louis, Mo), dosed at 30
mg/kg, was dissolved in drinking water. However, this
approach was not successful because it caused severe
hemorrhage at the anastomosis. As an alternative, heparin
(LEO Pharma, Ballerup, Denmark) was administered
intravenously at a dose of 0.2 IU/g body weight.
Surgical procedure. After the animal was anesthetized,
the eyes were covered with an Oculentum simplex ointment
(Pharmachemie BV, Haarlem, The Netherlands), and the
surgical area was shaved. The animal was ﬁxed supine on
a heating blanket. The skin was disinfected, and a ventral
midline incisionwasmade in the neck under anM80 dissect-
ing microscope (Leica, Wetzlar, Germany). After the dorso-
medial distal branch of the right external jugular vein was
dissected, a vascular clamp (S&T, Neuhausen, Switzerland)
was placed proximally and a 10-0 ligature (BBraun, Melsun-
gen, Germany) was placed distally, followed by transection
of the vein just proximal from the ligature (Fig 1). The
vein was rinsed with saline containing 100 IU/mL heparin.
Fig 2. Morphometric parameters and fragmentation of internal elastic lamina (IEL). Venous section in the arterio-
venous ﬁstula (AVF) stained with Weigert elastin. A, The IEL, traced in black, is used to quantify the circumference.
Intimal hyperplasia (IH) and luminal (lumen) area are shown. B, High magniﬁcation photomicrograph shows frag-
mentation of the IEL, which is indicated by the black arrow (original magniﬁcation, 100; scale bar: 100 mm).
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and ligated proximally and distally with a 6-0 suture thread
(BBraun). The muscle was then transected between the
two ligations with heat cautery (Fine Science Tools, Hei-
delberg, Germany). Next, the right common carotid artery
was dissected and clamped, followed by an incision of
w1.0 mm longitudinally with microscissors (Fine Science
Tools). The carotid artery was rinsed with heparin (100
IU/mL), whereupon the end of the vein was anastomosed
to the side of the artery using 10-0 interrupted sutures
(BBraun). Heparin (0.2 IU/g body weight) was injected
intravenously halfway during suturing. After completion
of the anastomosis, the remaining clamps were removed,
and patency was assessed. The skin was closed with a 6-
0 running suture (BBraun). A more detailed description
is available in the Supplementary data (online only).
After completion of the surgery, 0.5 mL saline was
injected subcutaneously, and the animals were kept warm
until full recovery. A preoperative patent AVF, followed
by a complete recovery from the anesthesia, was consid-
ered a surgical success.
Near-infrared ﬂuorescence imaging. To assess direct
postoperative AVF patency and at the time of euthanasia
at day 14 or day 28, near-infrared ﬂuorescence (NIRF)
imaging was used, as previously described.23,24 Each
animal received 200 mL via the femoral vein of a 500 mM
indocyanine green solution (Pulsion Medical Systems,
Munich, Germany) that was dissolved in a 20% human
serum albumin (Sanquin, Amsterdam, The Netherlands).
Directly after the injection, theﬂuorescence assisted resec-
tion and exploration (FLARE) imaging system (Center for
Molecular Imaging, Boston, Mass) was positioned approxi-
mately 46cmabove theAVF, and video imageswere captured
at 30 frames/s.Multiple video channels (color video, 700 and
800 nm) were obtained simultaneously with 60-milliseconds
(16.7-Hz) exposure times. After computer-controlled image
acquisition, color video andNIRF imagesweredisplayed indi-
vidually or merged in real-time. The 800-nm channel was
used for imaging indocyanine green.
Tissue harvesting and processing. Upon euthanasia,
animals received an intraperitoneal injection with an anes-
thetic mixture containing midazolam (5 mg/kg; Roche,Basel, Switzerland), medetomidine (0.5 mg/kg; Orion,
Espoo, Finland), and fentanyl (0.05 mg/kg; Janssen,
High Wycombe, UK), whereupon a repeat incision was
made through the scar. The AVF was dissected and patency
was assessed. After a thoracotomy, the inferior vena cava
was transected, followed by an intracardiac perfusion with
4% formalin. The tissue was processed to parafﬁn, and
5-mm sections of were made perpendicular to the vein
at 12 locations with an interval of 150 mm. The small
size of the murine vasculature and the conﬁguration of
the AVF preclude simultaneous perpendicular analysis
of the carotid artery and the jugular vein. Because most
of the stenotic lesions in human AVFs occur in the venous
outﬂow tract, we focused our analysis on the vein.
Morphometric analysis. Histochemical staining with
hematoxylin, phloxine, and saffron was used for a morpho-
logic overview. Fibrin deposition was assessed by using
Movat pentachrome staining. Morphometric analysis was
performed on sections stained with Weigert elastin. All
venous sections were analyzed using quantitative Qwin
imaging software (Leica). The intimal area was calculated
by subtracting the luminal area from the area within the
internal elastic lamina (IEL). The circumference of the
vessel was determined by the length of the IEL (Fig 2,
A). The percentage stenosis was deﬁned as the intimal area
divided by the intimal area plus the lumen area [intima/
(intima þ lumen)  100]. AVFs were deﬁned patent
histologically when the maximum stenosis percentage in all
included venous sections was #95%. In addition, the
venous sections were divided in four equal segments of
300 mm (Fig 3, C, A-D) by grouping two consecutive
slides starting from the area closest to the anastomosis.
Results are expressed as mean 6 standard error of the
mean.
Collagen quantiﬁcation. Collagen content was deter-
mined in Sirius red stained sections using Qwin quantitative
imaging software. This was measured in the whole vessel
and was expressed as total positive surface area (mm2) and
as positive area divided by the total vessel area (%).
Immunohistochemical analysis. Serial sections from
each AVF were stained with the following antibodies:
anti- a-smooth muscle actin (a-SMA) for vascular smooth
Fig 3. Quantiﬁcation of outward remodeling (OR) and intimal hyperplasia (IH). A,OR was present in the ﬁrst 14 days
after arteriovenous ﬁstula (AVF) creation. B, IH increased progressively in time, whereas the luminal area only
increased in the ﬁrst 14 days after AVF placement due to a reduction in OR after this time point. Furthermore, the
increase in IH between consecutive time points was signiﬁcant between days 14 and 28. C, The venous outﬂow tract
was divided in four equal segments of 300 mm (A-D) and shows that the maximum IH (shaded area) was located at the
site closest to the anastomosis. OR at days (D) 7, (E) 14, and (F) 28 and luminal area at days (G) 7, (H) 14, and (I) 28
were not differently distributed in the vein. At days 14 and 28, IH was the highest in the ﬁrst 600 mm. J, The total
amount of collagen increased in time. K,However, the amount of collagen divided by the total vessel area remained the
same between the control and arterialized vein. *P < .05 compared with control. **P < .05 compared with the
previous time point. Mean data are presented with the standard error of the mean (error bars).
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Fig 4. Visualization of the arteriovenous ﬁstula (AVF) with near-infrared ﬂuorescence imaging. The proximal carotid
artery and venous outﬂow tract are depicted by a red and blue arrow, respectively. A, Intravenous administration of
indocyanine green (white) that is detected at 800 nm using a ﬂuorescence-assisted resection and exploration (FLARE)
imaging system indicates AVF patency directly after completion of the surgical intervention. B,Merged image of color
video and 800-nm near-infrared ﬂuorescence channel. C, At 28 days after surgery, the luminal area is reduced in the
perianastomotic area due to intimal hyperplasia (IH).
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Dako, Glostrup, Denmark), anti-cluster of differentiation
(CD)31 for endothelial cells (1:200 dilution; Abcam,
Cambridge, UK); and anti-CD45 for leukocytes (1:200
dilution; BD Pharmingen, San Diego, Calif). Slides were
digitized at a resolution of 2080  1542 by a camera
connected to a microscope (Carl Zeiss, Oberkochen,
Germany). Detailed protocols of the stainings are listed in
the Supplementary data (online only)
Statistical analysis. Results are expressed as mean 6
standard error of the mean. Comparison between the
time points was performed by one-way analysis of vari-
ance, followed by a Tukey highly signiﬁcant difference test.
Differences were considered statistically signiﬁcant at
a value of P < .05.
RESULTS
Surgical outcome. The average time of the surgical
procedure was 60 minutes, and it was successful in 30 of
45 mice (67%). The main cause of failure was hemorrhage
(60%), followed by acute thrombosis (27%) and anesthesia-
related death (13%). In the group where the surgical
intervention was successful, three mice died postoperatively
of unknown causes, and one mouse developed a wound
abscess. These four mice were excluded from the study. Of
the remaining 26 mice, eight were euthanized at day 7, 10
at day 14, and eight at day 28 after surgery. The control
group comprised 11 animals without AVF surgery.
Patency. Patency of the AVF was assessed visually using
the dissecting microscope at euthanasia and was conﬁrmed
histologically. This resulted in patency rates of 88%, 90%,
and 50% at days 7, 14, and 28, respectively. Patency was
also assessed in 10 mice by NIRF. Fig 4 shows representa-
tive NIRF images of a patent AVF directly after creation
and at 28 days. The patency assessed by NIRF matched
the visual assessment in 10 of 11 mice (91%). In the
remaining mouse, the AVF appeared patent by NIRF, but
no perfusion could be observed macroscopically. A repre-
sentative video of the patency assessment using NIRF is
available in the Supplementary data (online only).Morphometric analysis. For the quantiﬁcation of OR
and IH, only patent AVFs were included in the analysis
(7, 8, and 4 mice for 7, 14, and 28 days of follow-up,
respectively).
OR. The venous circumference was higher at days 14
(2.36 6 0.15 mm) and 28 (2.45 6 0.24 mm) compared
with the circumference of the unoperated-on control
mice (1.33 6 0.30 mm; P ¼ .01 and P ¼ .037, respec-
tively). The highest increase in mean venous circumference
(1.4-fold) was observed within 7 days after surgery (1.336
0.30 vs 1.82 6 0.07 mm; P ¼ .443). Between days 7 and
14, a 1.3-fold increase was observed (P ¼ .397), whereas
no increase in venous circumference was observed from
days 14 to 28 (P ¼ .996; Fig 3, A).
No difference in OR was observed between various
sections of the AVF (Fig 3,D-F). Of note, the venous circum-
ference of the occluded AVFs (1.696 0.2 mm) at day 28 was
smaller compared with patent AVFs (2.45 6 0.2 mm) at the
same time point. In all AVFs, we observed fragmentation of
the IEL in the venous outﬂow tract (Fig 2, B).
IH and luminal area. Already at 7 days after surgery,
we observed IH (60,138 6 23,626 mm2) in the venous
outﬂow tract (Fig 5, B-D). This area further increased at
days 14 and 28 (115,090 6 22,594 and 234,619 6 47,828
mm2, respectively) and was signiﬁcantly higher compared
with control mice (2,368 6 1,056 mm2; P ¼ .001 and
P < .001, respectively; Fig 3, B). Detailed analysis of the
various sections within the venous outﬂow tract revealed
that IH was most prominent in the ﬁrst 600 mm from the
anastomosis (Fig 3, G-I). The combined effect of the OR
process and IH resulted in a markedly higher luminal area at
days 14 and 28 (173,965 6 30,829 and 164,842 6 63,411
mm2) compared with the control (24,679 6 8,462 mm2;
P < .001 and P ¼ .010, respectively). Between the
consecutive time points, we observed a 3.5-fold increase in
the luminal area at day 7 (85,6936 13,541 mm2) compared
with the control veins (P ¼ .294). Between days 7 and 14,
a twofold increase in lumen area was observed (P ¼ .082).
At day 28, the luminal area of the patent AVFs decreased by
5% compared with day 14 (P ¼ .996; Fig 3, B).
Fig 5. Outward remodeling (OR), intimal hyperplasia (IH), and collagen distribution are shown in time. Venous
sections stained with hematoxylin, phloxine, and saffron (HPS) at days 7, 14 and 28 after creation of arteriovenous
ﬁstula (AVF). A control vein (A) before arterialization shows no IH and has a modest circumference compared with
the veins (B-D) after AVF placement. OR was primarily observed at (B) day 7 and (C) day 14 and was less evident at
(D) day 28. E-H, Higher magniﬁcation photomicrographs of panels (A-D) shows the development of neo-IH,
which starts with a (F) thrombus that has been repopularized with cells as time progresses. I-L, Sirius red staining
shows the collagen content in time. M-P, Movat pentachrome staining shows ﬁbrin-rich areas (bright red) in the
intimal lesion at the different time points. (A-D, I-P: original magniﬁcation, 100; E-H: original
magniﬁcation, 400). Partially repopularized thrombus indicated by asterisk (*), and black arrow indicates ﬁbrin-rich
area. Scale bar: 100 mm.
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and 59%, respectively. At 7 days after surgery, the highest
percentage of stenosis was observed in the ﬁrst 300 mm
from the anastomosis (segment A). At days 14 and 28 after
surgery, the percentage stenosis was the highest in
segment A and B (data not shown). In the occluded
AVFs at day 28, IH was 23% lower compared with patent
vessels at the same time point (180,866 6 49,332 vs
234,619 6 47,828 mm2).
Composition of IH. Histologic analysis revealed
a dynamic composition of the intimal lesions. Starting
from day 7, the intimal lesion consisted mainly of an acel-
lular ﬁbrin-rich layer, consistent with a focal adherent
thrombus (Fig 5, B, F, N-P). Concomitant with increasedlesion size at later time points (days 14 and 28),
progressive cellular density was observed (Fig 5, F-H).
Most cells within the intima were positive for a-SMA
(Fig 6, B-D). Analysis of CD45-stained sections demon-
strated the presence of leukocytes, mainly in the adventitia
and outer circumference of the vessel wall at all time
points and in the intima starting at day 14 (Fig 6, F-H).
The endothelial layer was disrupted at all time points,
although CD31-positive cells did increase in time.
Furthermore, an increased density of adventitial capillaries
was observed starting from day 7 (Fig 6, J-L).
Quantiﬁcation of collagen content in the venous
outﬂow tract revealed a time-dependent increase in abso-
lute collagen content (Fig 3, J-K and Fig 5, J-L). However,
Fig 6. Immunohistochemical stainings. A, Immunohistochemical assessment of cells positive for a-smooth muscle
actin (SMA) revealed a small band in the control vein, compared with a (B-D) time-dependant increase of a-SMA-
positive cells in the intimal hyperplasia (IH) after arteriovenous ﬁstula (AVF) surgery. E, The presence of leukocytes,
which was absent in the control vein, was located in the (F-H) media and adventitia of the AVF vein at all time points.
H, However, leukocytes were also found in the intima at day 14 and 28 as depicted by the black arrow. J and K, The
luminal lining with cluster of differentiation (CD)31-positive endothelial cells, was disrupted at all time points but
showed re-endothelialization in a time dependant manner. L, Adventitial capillaries were present at all time points
(black arrow). I, The control vein showed an intact lining of endothelial cells. (A-D: original magniﬁcation,100; E-L:
original magniﬁcation, 200). The asterisk (*) indicates the lumen. Scale bar: 100 mm.
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between study mice and the control group, and at all
time points were expressed as a percentage of the total
vessel area. Thus, the relative contribution of collagen in
the total vessel composition remained stable.
DISCUSSION
In the present study, we describe a novel murine model
of AVF failure in which the AVF conﬁguration resembles
the human situation (venous end-to-arterial side). We
observed that the venous outﬂow tract of AVFs is charac-
terized by OR in the ﬁrst 14 days. Furthermore, we
hypothesize that focal adherent thrombi appear to serve
as fertile soil for the formation of progressive a-SMA-
positive intimal lesions, ultimately leading to a 50% loss
of patency at 28 days after surgery.
Anticoagulant therapy was necessary for creating
a patent AVF, and ﬁnding the correct balance between
acute thrombosis and hemorrhage proved to be of crucial
importance. Importantly, we observed a very high 69%
incidence of bleeding complications when acetylsalicylic
acid was used. Therefore, as an alternative, we administered
a single dose of heparin, which was effective in preventingacute thrombosis. Using our protocol with heparin, we
observed early thrombosis in 3% of the mice and bleeding
complications in 7%.
OR. Although IH is widely considered to be the most
important determinant of AVF failure, the functionality of
the AVF is generally determined by the luminal area, which
is deﬁned by the net result of OR and IH formation. To
the best of our knowledge, we are the ﬁrst to quantify
OR by measuring the circumference of the venous outﬂow
tract in a murine AVF model. Studies in rats and mice have
revealed that OR is induced by the increase in ﬂow that
evokes an adaptive response of the vessel in which the
luminal diameter increases in an attempt to reduce wall
shear stress to pre-AVF levels.8,25,26 In our study, we
observed a 1.4-fold increase in venous circumference
within 7 days after AVF placement. Unfortunately, data on
wall shear stress could not be collected. The decrease in
OR at later time points could be the result of the partial
normalization of shear stress levels, as previously observed
in murine26 and human27 AVF studies.
Furthermore, we observed fragmentation of the IEL of
the venous outﬂow tract, a phenomenon that has been
described in previous studies.28-30 This effect is likely
JOURNAL OF VASCULAR SURGERY
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and MMP-9 activation, a process that is essential in facili-
tating OR.28,29 In keeping with this notion, serum levels
of MMP-2 have been shown to be signiﬁcantly higher in
patients with matured AVFs compared with nonmatured
AVFs.31
We observed a smaller venous circumference in the
occluded AVFs at 4 weeks after surgery. The latter might
suggest that the cause of AVF failure in these mice could
potentially be the result of impaired OR. However, these
data should be interpreted with caution because we cannot
exclude the possibility that the circumference decreased
upon occlusion of the vessel.
IH formation. IH is designated as one of the main
contributors in the pathophysiology in failing human
AVFs and is typically located in the juxta-anastomotic
area of the venous outﬂow tract.32,33 In our study,
progressive IH developed in this same region of the
AVF, illustrating the resemblance to failing human AVFs.
Interestingly, we observed a remarkable pattern in the
development of IH not previously described in AVF
studies. In our murine AVFs, IH appeared to commence
with the focal adherence of thrombi. In the following
weeks, these lesions showed progressive cellularity, culmi-
nating in a high cellular density at 28 days. At this time,
intimal lesions possessed the hallmarks of classic IH of
failed human AVFs, as evidenced by the presence of high
numbers of a-SMA-positive cells.32,34
Thus far, IH is considered primarily to be the direct
result of migrating and proliferating VSMCs, and thrombus
formation in the early phase after surgery would be consid-
ered a separate entity.5,11,13,35 Although the venous
morphology in the early phase after AVF surgery has not
been described in great detail in humans, the sequence of
events in the development of IH in our study does resemble
the pathophysiology of intimal lesions after (arterial) angio-
plasty and in vein grafts.36,37 Furthermore, Castier et al5
also showed partly acellular lesions in the venous outﬂow
tract of murine AVF. The adherence of small (platelet
and ﬁbrin-rich) thrombi to the vessel wall most likely results
from endothelial denudation and the subsequent exposure
of the subendothelial matrix, leading to platelet adhesion
and activation.36,38,39 Indeed, we observed marked endo-
thelial denudation in the venous outﬂow tract in the ﬁrst
7 days after surgery, a phenomenon that also was observed
in previous animal studies of AVF failure.8,11
This observation might suggest that anticoagulatory
interventions could be an eligible strategy to inhibit IH.
Previous studies in a murine vascular endothelial injury
model indeed revealed reduced IH upon treatment
with human soluble CD39, an inhibitor of adenosine
diphosphate-mediated platelet activation.40 In contrast,
a randomized clinical controlled trial by Dember et al41
showed no signiﬁcant effect on AVF maturation, despite
a reduction in incidence of early thrombosis in patients
treated with clopidogrel. In our opinion, the limited effect
of systemic antiplatelet therapy on AVF maturation inhumans does not necessarily preclude a contributing role
of platelets in local development of IH in AVF.
Role of inﬂammation in vascular adaptation in
AVFs. The inﬂammatory response is a crucial process
involved in vascular injury and is linked to development
of IH.37,39,42 Upon injury, leukocytes are recruited via
activated platelets lining the denuded endothelium and
release chemokines, such as monocyte chemotactic
protein-143 and interleukin 6 and 8, which further stimu-
late leukocyte recruitment.42 Similar to the pathophysi-
ology in occlusive vein graft disease and arterial restenosis,
we observed a marked inﬂux of leukocytes at the adventitial
side of the vein throughout all time points. In contrast,
hardly any CD45-positive cells were present in the intima
in the ﬁrst 14 days. This might suggest that leukocyte
inﬁltration in the early phase predominantly occurs via
adventitial capillaries rather than the lumen,44,45 as
demonstrated by Gotoh et al.45 However, the role of
inﬂammation in OR in the AVF has gained little attention.
Future experiments using anti-inﬂammatory therapeutic
agents could aid in the elucidation of the contribution of
inﬂammation in AVF remodeling.
Animal models. In concordance with other rodent
AVF models,5,7,8,11-13 we observed rapid development of
IH. Furthermore, as previously described in AVF studies in
rats,8 marked venous OR was observed in the ﬁrst 14 days
after surgery. As a result of this venous OR, we observed an
increase in luminal area in the ﬁrst 14 days, whereas Castier
et al5 described a decrease in luminal area from the ﬁrst
week after AVF creation. In the Castier study, however, the
arterial rather than the venous segment of the AVF was
analyzed. Together with the difference in AVF conﬁgura-
tion, this might explain the observed difference in luminal
area, because previous studies in rats have revealed that
arterial OR is less prominent than venous OR.8 However,
this explanation remains speculative because Castier et al
did not report data on OR.
NIRF imaging. We were unable to visualize the AVF
with conventional techniques such as ultrasound imaging
and magnetic resonance imaging. Therefore, we used
NIRF technology, which proved to be a quick and accurate
method to assess the patency of murine AVFs.
Study limitations. Although animal models are useful
in gaining insight into the pathophysiology of various human
diseases, we should remain cautious in the interpretation
and extrapolation of these results because the pathology
in animals does not necessarily mimic that of humans.
A multitude of risk factors, including the uremic milieu
and the hemodialysis procedure itself are likely to contribute
to premature vascular diseases.46,47 Uremia can play a major
role in this regard, and more speciﬁcally, can directly lead to
venous IH in end stage renal disease patients before hemo-
dialysis access surgery.48 Incorporation of chronic renal
failure in mice, as described by Kokubo et al,35 will be
considered in future studies.
The complex microsurgical procedure remains a chal-
lenge that requires a skilled surgeon. However, the surgical
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200 Wong et al January 2014difﬁculty is comparable to the existing murine AVF model
as described by Castier et al.5 Importantly, sufﬁcient
training has led to a 97% surgical success rate during
ongoing experimental studies.
CONCLUSIONS
We describe a novel murine AVF model with a conﬁg-
uration similar to the one used most frequently in humans.
This end-to-side conﬁguration, while providing a more
accurate reﬂection of human AVF pathophysiology, can
also yield novel insight into this process by being effectively
applied in a myriad of transgenic animals. In view of the
different proposed mechanisms that are involved in venous
remodeling in the AVF, disabling genes that play an impor-
tant role in coagulation, inﬂammation, and VSMC biology
can help us to elucidate the complex pathophysiology of
AVF failure. We hope the knowledge obtained from these
studies will result in the development of new therapeutic
strategies that improve the patency of AVFs in patients
who require hemodialysis.
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Surgical procedure. After the animal was anesthe-
tized, its eyes were covered with Oculentum simplex oint-
ment (Pharmachemie BV, Haarlem, The Netherlands),
and the surgical area was shaved. Next, the animal was ﬁxed
supine on a heating blanket. The skin was disinfected with
ethanol, and a ventral midline incision was made in the
neck under an M80 dissecting microscope (Leica, Wetzlar,
Germany). After the dorsomedial distal branch of the right
external jugular vein was dissected, a vascular clamp (B1-V;
S&T, Neuhausen, Switzerland) was placed proximally, and
a 10-0 ligature (BBraun, Melsungen, Germany) was placed
distally, followed by transection of the vein just proximal
from the ligature (Fig 1, A-E). The vein was then rinsed
with saline containing 100 IU/mL heparin.
The right sternocleidomastoid muscle was dissected
and ligated proximally and distally with a 6-0 suture thread
(BBraun). The muscle was transected between the two
ligations with heat cautery (Fine Science Tools, Heidel-
berg, Germany). Next, the right common carotid artery
was dissected and clamped, followed by an incision with
microscissors (Fine Science Tools, Heidelberg, Germany)
of w1.0 mm longitudinally.
The carotid artery was rinsed with saline containing
100 IU/mL heparin, whereupon the end of the vein was
anastomosed to the side of the artery using 10-0 interrup-
ted sutures. The ﬁrst two interrupted sutures were inserted
at the 12 and 6 o’clock position of the vein and at the ends
of the incision in the artery, providing mild tissue tension
and a good starting position by dividing the suture area
of the vein in two even portions. Tension was then also
applied longitudinally using a 6-0 suture thread (BBraun)
that was placed below the vein, followed by placement of
interrupted 10-0 sutures at the exposed half of the anasto-
mosis. Next, heparin was injected intravenously in the
femoral vein at a dose of 0.2 IU/g body weight.
The rear, unexposed part of the anastomosis was then
exposed by a 180 axial rotation of the arterial clamps
and the partly anastomosed vein with the help of a suture
thread that now was placed above the vein and below the
artery. The venous clamp was removed during the rota-
tional procedure. After completion of the anastomosis,
the remaining arterial clamps were removed, starting with
the distal clamp. After conﬁrming the patency of theAVF, the skin was closed with a 6-0 running suture
(BBraun).
Immunohistochemistry. For immunohistochemical
stainings, deparafﬁnization and hydration was followed by
a treatment with 1% hydrogen peroxide and 5% bovine
serum albumin to block the endogenous peroxidase and
aspeciﬁc binding sites, respectively. Antigen retrieval in
the anticluster of differentiation (CD)31 and CD45 stain-
ing consisted of a treatment with 0.1% trypsin (Sigma-
Aldrich, St. Louis, Mo) for 30 minutes at 37C.
Incubation of the primary antibodies was performed
overnight at room temperature. Subsequently, sections
were incubated at room temperature for 1 hour with
horseradish peroxidase-labeled antibodies against mouse
immunoglobulin (Ig)G (Dako, Glostrup, Denmark) in
the a-smooth muscle actin staining (1:1000 dilution) and
rabbit IgG (Envision, Dako) in the staining against
CD31. Biotinylated antirat antibody (Vector Laboratories,
Burlingame, Calif) was used in the stainings against CD45,
followed by treatment with a 0.2 % streptavidin-AB
complex (Dako) for 30 minutes at room temperature.
Immunoreactive tissue was then developed by using
a 3,30-diaminobenzidine peroxidase substrate kit (Dako).
Sections were counterstained with hematoxylin.
Near-infrared ﬂuoroscopy
Video 1. Near-infrared ﬂuorescence imaging was used to
visualize a patent arteriovenous ﬁstula directly after crea-
tion. A total of 200 mL indocyanine green adsorbed to
human serum albumin (500 mM) was injected intrave-
nously in the femoral vein. The ﬂuorescent signal of indoc-
yanine green was pseudo-colored green and merged with
the color video.
Video 2. Near-infrared ﬂuorescence imaging was used to
visualize a patent arteriovenous ﬁstula 28 days after crea-
tion. A total of 200 mL indocyanine green adsorbed to
human serum albumin (500 mM) was injected intrave-
nously in the femoral vein seconds after the start of the
recording. The ﬂuorescent signal of indocyanine green
was pseudo-colored green and merged with the color
video. The video shows direct antegrade ﬁlling of the
venous outﬂow tract demonstrating a patent arteriovenous
ﬁstula.
